Pathology: mEC - (neo)adjuvant (NA); mEC - 1st line (L1); mEC - 2nd line (L2);
| mEC - (neo)adjuvant (NA) | mEC - 1st line (L1) | mEC - 2nd line (L2) | ||||
| CheckMate 577, 2021 | KEYNOTE-590, 0 | ESCORT, 2020 | ATTRACTION-3, 2019 | KEYNOTE-181, 2020 | ||
| nivolumab alone | 2 | T1 | T1 | |||
| pembrolizumab plus SoC | 1 | T1 | ||||
| camrelizumab alone | 1 | T1 | ||||
| pembrolizumab alone | 1 | T1 | ||||
| placebo plus SoC | 0 | T0 | ||||
| placebo | 0 | T0 | ||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | ||